Digest Network Come funziona
Network
/
Società
Pr
Non verificato

Prolong Pharmaceuticals, LLC

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
30/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Prolong’s Investigational Therapy for Acute Ischemic Stroke, PP-007, Receives FDA Breakthrough Therapy Designation
Fonte
Prolong Pharmaceuticals, LLC
Emittente
Business Wire
1.00
0
05/02/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)
Fonte
Prolong Pharmaceuticals, LLC
Emittente
Business Wire
1.00
0
13/11/2024
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)
Fonte
Prolong Pharmaceuticals, LLC
Emittente
Business Wire
1.00
0
30/10/2024
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study
Fonte
Prolong Pharmaceuticals, LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0